Pazopanib Intermediate

Détails du produit

Pazopanib intermédiaire is a relatively new type of pharmaceutical intermediate. This substance is mainly used in various anticancer drugs. It can well interfere with the survival of some tumor substances and can also help generate various vascular inhibitors. It can effectively act on the vascular endothelium and play a good therapeutic role by inhibiting tumor blood supply.

Pazopanib is a polytyrosine kinase inhibitor that targets:

Vascular endothelial growth factor receptor: VEGFR-1, VEGFR-2, VEGFR-3;

Platelet-derived growth factor receptors: PDGFR-α, PDGFR-β;

Fibroblast growth factor receptors: FGFR-1, FGFR-3;

Cytokine receptors (Kit);

Interleukin-2 receptor-induced T-cell kinase (Itk);

Lymphocyte-specific tyrosine kinase (Lck);

Transmembrane glycoprotein receptor tyrosine kinases (cFms).

Pazopanib can selectively inhibit VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β and Kit, and by blocking tyrosine kinases, it can destroy the information transmission of tumor cells, thereby inhibiting tumor cells Proliferation and angiogenesis, so as to achieve the purpose of anti-tumor.

Avantages pour la santé

In clinical practice, pazopanib is mainly used to interfere with the formation of new blood vessels required for the survival and growth of refractory tumors. It is a new type of oral angiogenesis inhibitor that targets vascular endothelial growth receptors clinically, and plays a role by inhibiting the formation of new blood vessels for tumor blood supply. It is mainly suitable for advanced renal cells in clinical Carcinoma, soft tissue sarcoma, epithelial ovarian cancer and non-small cell lung cancer treatment. However, it can cause severe hepatotoxicity, so liver function should be measured regularly before and during treatmen.